vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Blue Foundry Bancorp (BLFY). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -27.4%, a 50.9% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 34.2%). Over the past eight quarters, Blue Foundry Bancorp's revenue compounded faster (16.0% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
ABUS vs BLFY — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $13.3M |
| Net Profit | $2.5M | $-3.5M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | -27.4% |
| Revenue YoY | 522.2% | 34.2% |
| Net Profit YoY | 112.7% | -30.6% |
| EPS (diluted) | $0.01 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $10.7M | $12.0M | ||
| Q1 25 | — | $11.1M | ||
| Q4 24 | — | $9.9M | ||
| Q3 24 | — | $9.5M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $-3.5M | ||
| Q3 25 | — | $-1.9M | ||
| Q2 25 | $2.5M | $-2.0M | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $-4.0M | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $-2.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -27.4% | ||
| Q3 25 | — | -14.8% | ||
| Q2 25 | 23.5% | -16.2% | ||
| Q1 25 | — | -24.2% | ||
| Q4 24 | — | -28.4% | ||
| Q3 24 | — | -42.7% | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | — | $-0.18 | ||
| Q3 25 | — | $-0.10 | ||
| Q2 25 | $0.01 | $-0.10 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 24 | — | $-0.12 | ||
| Q3 24 | — | $-0.19 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $53.1M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $312.7M |
| Total Assets | $103.3M | $2.2B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $53.1M | ||
| Q3 25 | — | $44.1M | ||
| Q2 25 | $37.4M | $41.9M | ||
| Q1 25 | — | $46.2M | ||
| Q4 24 | — | $42.5M | ||
| Q3 24 | — | $76.1M | ||
| Q2 24 | — | $60.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $312.7M | ||
| Q3 25 | — | $314.4M | ||
| Q2 25 | $83.0M | $321.3M | ||
| Q1 25 | — | $326.7M | ||
| Q4 24 | — | $332.2M | ||
| Q3 24 | — | $339.3M | ||
| Q2 24 | — | $345.6M | ||
| Q1 24 | — | $350.2M |
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $103.3M | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-8.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.0M | ||
| Q3 25 | — | $-255.0K | ||
| Q2 25 | $-15.7M | $2.0M | ||
| Q1 25 | — | $-3.8M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $14.1M | ||
| Q1 24 | — | $-4.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-4.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 49.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -49.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
